when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

GLP-1 receptor · news · pharmadog

← back to GLP-1 receptor

News · GLP-1 receptor

341 stories

Jun 2, 26Opinion: The virtual end of the doctor’s office waiting roomstat

Jun 1, 26STAT+: Medicare’s mum on GLP-1s, and Massachusetts sues Unitedstat

Jun 1, 26Opinion: What should hospitals do when patients demand unvaccinated donor blood?stat

Jun 1, 26CDC says containing the spread of Ebola is top prioritystat

Jun 1, 26Lilly licenses GLP-2 asset from Korean biotech Hanmi for $75M upfrontendpoints

Jun 1, 262026 Orphan Drugs Report: A safe(r) passage amid stormy waters?biopharma dive

Jun 1, 26Opinion: The military’s medical corps has a serious recruitment problemstat

Jun 1, 26Opinion: Medical schools diversified. So where are all the diverse doctors?stat

Jun 1, 26STAT+: Medicare still won’t say how much covering obesity drugs will coststat

May 29, 26Which vaccines will curb the Ebola outbreak? WHO debatesstat

May 29, 26Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’stat

May 28, 26Lilly obesity meds Foundayo and Zepbound to gain CVS coverageendpoints

May 28, 26For wearables, it’s a GLP-1 worldendpoints

May 28, 26CVS obesity drug deal puts Lilly on equal footing with Novobiopharma dive

May 19, 26STAT+: Dexcom CEO hints at future uses for CGMstat

May 18, 26Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drugbiopharma dive

May 18, 26STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much morestat

May 15, 26FDA hold puts Aardvark Prader-Willi drug in limbobiopharma dive

May 15, 26India’s pharma industry is going global. But can it catch up to China?biopharma dive

May 14, 26Dr Jones on the Protective Benefit and Tolerability of GLP-1 Agonists vs Aspirin for CRC Preventiononclive

May 13, 26Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisisstat

May 13, 26Lilly data point to ‘maintenance’ strategies for GLP-1 weight lossbiopharma dive

May 13, 26The ‘velocity of obesity’ aims to show which nations are slowing an epidemicstat

May 13, 26STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and morestat

May 12, 26Males who discuss suicide seek help less often than females, report findsstat

May 12, 26STAT+: Hims takes a $33 million hit from GLP-1 ‘pivot’stat

May 12, 26A year after Vertex’s big launch, pain drug research faces a pivotal momentbiopharma dive

May 11, 26Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trialbiopharma dive

May 11, 26European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapyendpoints

May 8, 26Lilly, Gilead lead pharma’s M&A boombiopharma dive

← prevpage 11 of 12next →